Innovations in cancer drug discovery: A new opportunity for serendipity

Programme stream(s): Cancer discovery / underpinning research , Treatment
Programme session type(s): Parallel session

Chair: Neil Carragher, University of Edinburgh
Speaker: Arpita Ray, Benevolent AI. London
Speaker: Susanne Mueller-knapp, Structural Genomics Consortium, Frankfurt
Speaker: Asier Uniciti Broceta, University of Edinburgh

5:05 pm-6:35 pm

Room: Boisdale

Recent advances in cell-based screening, organoids, CRISPR-gene editing, agile chemical design and high quality chemical probe libraries are enabling a more robust hypothesis-generating approach to cancer drug discovery under appropriate disease context. Such developments complemented by advances in bioinformatics and emerging artificial intelligence solutions provide a new opportunity for serendipity to innovate and accelerate cancer drug discovery towards new biological target space and increased clinical success.

Our speakers will present the latest developments in:
Artificial Intelligence in cancer drug discovery; Expansion of high quality chemical probe libraries for target discovery and validation; Innovative chemical design based on cancer cell phenotypes.